Heart failure & cardiomyopathiesMeta-analysis
Early effects of SGLT2 inhibitors in acute heart failure: an individual patient-level meta-analysis
- Individual patient-level meta-analysis of randomised controlled trials
Authors' conclusion
SGLT2i therapy, initiated early in admission for acute HF, increased diuresis and reduced the risk of post-discharge mortality and HF readmission.
Study context
- Population
- Patients with acute heart failure (HF)
- Participants
- 623 patients · 6 trials
- Comparison
- SGLT2 inhibitors vs placebo/control
- Outcome
- 24-h diuresis
- Follow-up
- 24 h
Pooled result
As reported in the abstract
P < 0.001
Further pooled results
| Outcome | adjusted HR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortality and HF rehospitalization (composite) · 60 days | 0.62 (0.41–0.95) | P = 0.028 | |
| 0.512Adjusted hazard ratio (log scale) |
| Outcome | win ratio (95% CI) | P value | |
|---|---|---|---|
| Win ratio (death, HF rehospitalization, 24-h diuresis) | 1.45 (1.16–1.82) | P = 0.001 | |
| 0.512Win ratio (log scale) |
Diuresis through Day 5
- Effect of SGLT2i on diuresis persisted through Day 5
Natriuresis
- SGLT2i did not increase natriuresis at any timepoint
Subgroup analyses
- Subgroup analyses did not differ between groups
Original publication
Early effects of SGLT2 inhibitors in acute heart failure: an individual patient-level meta-analysis. Eur J Heart Fail. Published 23 June 2026. doi:10.1093/ejhf/xuag184
Summarised from the published abstract; every number is checked against it